Thomas Liquard

Thomas Liquard has a diverse work experience in the pharmaceutical and biotech industry. Thomas started their career in 2004 as a Senior Consultant at The Frankel Group. In 2007, they joined Pfizer and held various roles including Director of US New Product Planning and Senior Director of Portfolio Development, Emerging Markets.

In 2013, Thomas became the Chief Executive Officer of Alchemia Limited before moving to Immuron in 2015 to serve as the Chief Executive Officer. During this time, they also held positions as Director on the Board of Directors for PharmaCyte Biotech and Dreamcity Melbourne.

In 2017, Thomas worked as the Senior Vice President of Corporate Development at Neurelis, Inc. and then joined Bastion Biologics in 2018 as the Executive Director of the Board of Directors.

Throughout their career, Thomas has shown a strong expertise in corporate development, executive management, and strategic planning in the pharmaceutical industry.

Thomas Liquard received a Bachelor of Science and Bachelor of Arts degree in Marketing from USC Marshall School of Business. Thomas went on to pursue an MBA in Finance and Management of Organizations from Columbia Business School, which they obtained in 2001.